Blood transfusions happen in more than [10%](http://www.hcup-us.ahrq.gov/reports/factsandfigures/2009/section3_TOC.jsp){#interrefs10} of all hospital stays that include a procedure. The American Medical Association[@bib1] identified overuse of five medical treatments---blood transfusions, along with cardiac stents, ear tubes, antibiotics, and the induction of birth in pregnant women---and highlighted the danger of unnecessary transfusions. Although blood transfusions are believed to be lifesaving, this assumption has never been shown in a controlled clinical trial; blood transfusions have been described as "unavoidably, unsafe, and inherently dangerous" in the US Blood Shield laws.[@bib2] Thus, perceived benefits relative to the known risks of a blood transfusion are important elements in discussions with patients about informed consent, especially in management of anaemia with alternatives to blood transfusion.[@bib3]

Transfusion-transmitted infections have been a worry, especially in the 1980s with the recognition of transfusion-associated HIV and the risk of transmission of hepatitis C virus.[@bib4] Transmission of known viral agents has decreased and responses to emerging infectious diseases transmitted by blood transfusion have been rapid ([figure](#fig1){ref-type="fig"} ). Concomitantly, the 2011--12 annual report of transfusion fatalities by the US Food and Drug Administration Center for Biologics Evaluation and Research showed a decrease in all-cause deaths related to transfusion, with only 30 deaths attributable to transfusion reported in the USA in 2011.[@bib5] Between 20×07 and 2011, transfusion-related acute lung injury caused the highest percentage (43%) of reported fatalities, followed by haemolytic transfusion reactions (23%) caused by non-ABO (13%) or ABO (10%) incompatibilities.FigureRisks of major transfusion-transmitted viruses related to interventions, and accelerating rate of emerging infectious diseases of concern to blood safetyEvolution of the risks of transmission by blood transfusion for HIV, hepatitis B virus, and hepatitis C virus. Major interventions to reduce risks are shown below the time line on the X axis. Emerging infectious disease threats in the past 20 years are shown above in the top right quadrant of the [figure](#fig1){ref-type="fig"}. HBsAg=hepatitis B surface antigen. Ab=antibody. NANB=non-A, non-B hepatitis. Ag=antigen. HCV=hepatitis C virus. NAT=nucleic acid testing. HBV=hepatitis B virus. ICL=idiopathic CD4 T-lymphocytopenia. vCJD=variant Creutzfeldt-Jakob disease. PTLVs=primate T lymphotropic viruses. SFV=simian foamy virus. WNV=West Nile virus. SARS=severe acute respiratory syndrome. DENV=dengue virus. CHIKV=chikungunya virus. XMRV=xenotropic murine leukaemia virus-related virus. Reproduced with permission from [@bib4].

Increasing evidence suggests that patients have additional adverse clinical outcomes (ie, increased morbidity and mortality) associated with blood transfusions.[@bib6] The [panel](#box1){ref-type="boxed-text"} lists risks that include not only known transmissible pathogens for infectious disease, transfusion reactions, transfusion-related acute lung injury, errors in blood administration, and circulatory overload; but also potential, as yet undefined, risks such as immunomodulation (eg, perioperative infection or tumour progression), unknown risks (emerging pathogens such as new variant Creutzfeldt-Jakob disease and West Nile virus),[@bib4] and risks associated with duration of blood storage lesions in patients undergoing cardiac surgery.[@bib7] The potential threat of xenotropic murine leukemia virus-related virus (XMRV), for example, required extensive research to determine that its presence in the blood of patients with chronic fatigue syndrome could not be reproducibly confirmed, and that blood donor screening is not warranted.[@bib8] PanelPotential risks of blood transfusion1Infectious agents•Transfusion-transmitted disease for which donors are tested[\*](#fn1){ref-type="fn"}•Hepatitis B virus (1970 \[surface antigen\]; 1986--87 \[core antibody\]; 2009 \[nucleic acid\])•HIV (1985 \[antibody\]; 1999 \[nucleic acid\])•Hepatitis C virus (1986--87 \[alanine aminotransferase\]; 1990 \[antibody\]; 1999 \[nucleic acid\])•Human T-cell lymphotropic virus (1988 \[antibody\])•West Nile virus (2003 \[nucleic acid\])•Bacteria (in platelets only; 2004)•*Trypanosoma cruzi* (2007 \[antibody\])•Cytomegalovirus•Syphilis•Transfusion-transmitted disease for which donors are not routinely tested•Hepatitis A virus•Parvovirus B19•Dengue fever virus•Malaria•*Babesia* spp•*Plasmodium* spp•*Leishmania* spp•*Brucella* spp•New variant Creutzfeldt-Jakob disease prions•Unknown pathogens2Transfusion reactions3Alloimmunisation4Medical errors (wrong blood to patient because of mislabelled specimen or patient misidentification)5Transfusion-associated acute lung injury6Transfusion-associated circulatory overload7Iron overload8Immunomodulation9Storage lesions (age of blood)

These considerations have given rise to the specialty of blood management, supported by [corresponding initiatives](http://www.sabm.org/){#interrefs20} to "promote the appropriate use of blood and blood components, with a goal of minimizing their use". This movement has been motivated by the need to improve blood safety and patient outcomes, preserve the blood inventory, and constrain escalating costs.[@bib9] Patient blood management has been recognised by WHO as a means to "promote the availability of transfusion alternatives".[@bib10] In 2010, blood management was cited as one of the ten key advances in transfusion medicine in the past 50 years.[@bib11]

Awareness of risks, costs, and the effect on blood inventory has led providers to look at institution-based initiatives in patient blood management, such as the use of guidelines restricting use of transfusion to improve blood use.[@bib12] Patient blood management encompasses an evidence-based medical and surgical approach that is multidisciplinary (ie, including transfusion medicine specialists, surgeons, anaesthesiologists, and critical care specialists) and multiprofessional (ie, including physicians, nurses, pump technologists, and pharmacists). In this approach, preventive strategies are emphasised to identify, assess, and manage anaemia in medical[@bib13] and surgical[@bib14] patients, including use of pharmacological interventions[@bib15] and the avoidance of unnecessary diagnostic teting to minimise iatrogenic blood loss;[@bib16] to optimise homoeostasis[@bib17] and use of point-of-care testing;[@bib18] and to establish clinical practice guidelines for blood transfusions. With recent development of quality--performance indicators for patient blood management by health-care institutions and accreditation organisations,[@bib3] the accompanying Clinical Series in *The Lancet* is appropriate and timely, and looks at the effect of patient blood management on three areas of transfusion medicine: blood utilisation, alternatives to blood, and inventory management of the blood supply.
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